Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions.

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical ...

Inhalation therapy is central to the treatment of patients with COPD, a condition that affects an estimated 480 million ...

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

The Digital Dose Inhalers Market is set for strong growth through 2031, driven by rising respiratory diseases and demand for smart, accurate drug delivery. Sai Kiran DataM Intelligence 4Market ...

Long-acting muscarinic antagonists, as add-on therapy to inhaled corticosteroids, improve lung function parameters and reduce ...